AR036689A1 - La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame - Google Patents

La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame

Info

Publication number
AR036689A1
AR036689A1 ARP020103656A ARP020103656A AR036689A1 AR 036689 A1 AR036689 A1 AR 036689A1 AR P020103656 A ARP020103656 A AR P020103656A AR P020103656 A ARP020103656 A AR P020103656A AR 036689 A1 AR036689 A1 AR 036689A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
same
administration
composition
propanol
Prior art date
Application number
ARP020103656A
Other languages
English (en)
Inventor
Alexander Wirl
Andre Gerard Bubendorf
Rolf-Dieter Gabel
Michael Hennig
Siegfried Krimmer
Guenter Neugebauer
Walter Preis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR036689A1 publication Critical patent/AR036689A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las formas pseudopolimórfica de (1) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)-etilamino]-2-propanol (carvedilol) o de formas ópticamente activas o sales farmacéuticamente aceptables de la misma. Se provee una mejora en la resorción del carvedilol especialmente en el caso de administración per oral y aquí especialmente en las regiones inferiores del intestino usando agentes disponibles en la tecnología farmacéutica. También se divulga el uso de la misma, y una composición farmacéuticamente aceptable que la comprende, un procedimiento para la producción de la composición, una forma de administración farmacéuticamente aceptable de la composición y el uso de la composición o de la forma de administración farmacéuticamente aceptable.
ARP020103656A 2001-09-28 2002-09-27 La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame AR036689A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123422 2001-09-28

Publications (1)

Publication Number Publication Date
AR036689A1 true AR036689A1 (es) 2004-09-29

Family

ID=8178782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103656A AR036689A1 (es) 2001-09-28 2002-09-27 La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame

Country Status (20)

Country Link
US (3) US20030119893A1 (es)
EP (1) EP1432681B1 (es)
JP (1) JP2005507899A (es)
KR (1) KR100752549B1 (es)
CN (1) CN1308307C (es)
AR (1) AR036689A1 (es)
AT (1) ATE369339T1 (es)
AU (1) AU2002338726B2 (es)
BR (1) BR0212927A (es)
CA (1) CA2460486A1 (es)
DE (1) DE60221683T2 (es)
ES (1) ES2291503T3 (es)
GT (1) GT200200198A (es)
MX (1) MXPA04002826A (es)
PA (1) PA8555201A1 (es)
PE (1) PE20030448A1 (es)
PL (1) PL370412A1 (es)
RU (1) RU2308449C2 (es)
UY (1) UY27461A1 (es)
WO (1) WO2003029214A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501191A (ja) * 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
CN1298322C (zh) 2002-01-15 2007-02-07 特瓦制药工业有限公司 卡维地洛的结晶固体及其制备方法
US7268156B2 (en) 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
SI21616A (sl) * 2003-09-02 2005-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalne oblike karvedilola
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
EP1991527A2 (en) * 2006-06-28 2008-11-19 Teva Pharmaceutical Industries Ltd Polymorphous forms of carvedilol phosphate
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
JP2004501191A (ja) * 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール

Also Published As

Publication number Publication date
ES2291503T3 (es) 2008-03-01
US20040198812A1 (en) 2004-10-07
DE60221683T2 (de) 2008-04-30
ATE369339T1 (de) 2007-08-15
MXPA04002826A (es) 2004-07-02
KR100752549B1 (ko) 2007-08-30
PL370412A1 (en) 2005-05-30
PA8555201A1 (es) 2003-12-10
EP1432681A1 (en) 2004-06-30
AU2002338726B2 (en) 2007-03-15
BR0212927A (pt) 2004-10-13
AU2002338726B9 (en) 2003-04-14
CA2460486A1 (en) 2003-04-10
GT200200198A (es) 2003-06-19
WO2003029214A1 (en) 2003-04-10
RU2004113209A (ru) 2005-05-20
US20030119893A1 (en) 2003-06-26
UY27461A1 (es) 2003-06-30
RU2308449C2 (ru) 2007-10-20
KR20040047872A (ko) 2004-06-05
CN1308307C (zh) 2007-04-04
US20060148878A1 (en) 2006-07-06
CN1558900A (zh) 2004-12-29
JP2005507899A (ja) 2005-03-24
DE60221683D1 (en) 2007-09-20
PE20030448A1 (es) 2003-06-19
EP1432681B1 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
AR036689A1 (es) La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame
PA8505201A1 (es) Aminoacidos biciclicos como agentes farmaceuticos
AR025962A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que los contienen
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
CO5060503A1 (es) Formulaciones farmaceuticas
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
CO5611096A2 (es) Forma de dosificacion farmaceutica para administracion mucosal
AR040118A2 (es) Metodo para dispensar anteojos electroactivos
UY25108A1 (es) Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen.
DOP2003000708A (es) Formulaciones que comprenden un compuesto a base de indolinona
ES2157881T3 (es) Metanosulfonato de paroxetina.
AR024773A1 (es) 9-arilsulfonas e intermediarios.
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
MX9300399A (es) Derivados heterotriciclicos.
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
GT200600403A (es) Composiciones y formas de dosificacion farmaceuticas
AR039253A1 (es) Asociacion de un antitrombotico y de aspirina
AR042297A1 (es) Forma de dosificacion oral de liberacion inmediata
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.
ES2151383B1 (es) Derivado de hidroquinona, sus sales de hidrocloruro agente antialergico que lo comprende y farmaco antialergico correspondiente.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal